137 results about "B polymyxin" patented technology

The present invention provides a method for separation purification of polymyxin B1 from a polymyxin B mixed component. The method comprises: (a) loading a chromatography medium of a macroporous absorption resin to obtain a chromatography column; and (b) adding a polymyxin B solution, and adopting an organic solvent-containing acid solution as an eluent to sequentially elute various components of the polymyxin B so as to obtain the polymyxin B1 solution after elution. According to the method, the operation is simple, the adopted separation medium has characteristics of stable chemical characteristic and high re-use rate, industrial scale-up is easily achieved, and the peak purity of the obtained polymyxin B1 can be more than 98%.

The present invention relates to an endotoxin adsorbent which is composed by taking spherical porous cellulose as a carrier and immobilizing effective amount of polymyxin B in the endotoxin adsorbent for blood perfusion as a ligand. The preparation method of the endotoxin adsorbent includes that the spherical porous cellulose is taken as the carrier, the spherical porous cellulose first reacts with sodium periodate and is bonded with the effective amount of polymyxin B, and the endotoxin adsorbent is obtained after reduction by sodium borohydride. The endotoxin adsorbent has the advantages of stable performance, large supported quantity of polymyxin B, good adsorption effect, etc.

The invention provides novel polypeptin with biological prevention and control and medical application potential values, and application thereof. The polypeptin has a structure shown in a formula (I). The invention has the main advantage of providing the polypeptin with toxicity lower than that of polymyxin B and biological prevention and control and medical application values, and a preparation method and application thereof. In-vitro experiments show that the compound has a remarkable inhibiting effect on gram-positive bacteria, gram-negative bacteria and fungi; and in-plate cultivation experiments show that the compound has certain prevention and control effects on a plurality of fungal plant diseases and particularly has the most remarkable prevention and control effects on rhizoctonia solani.

The invention relates to a preparation method of an endotoxin adsorbent. The spherical porous cellulose is taken as a carrier; the spherical porous cellulose is activated by triazine trichloride, coupled with triethyl phosphate, then immobilized polymyxin B, thus the endotoxin adsorbent is obtained. The endotoxin adsorbent obtained by the method has stable performance and good adsorption property.

Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi-3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 μM, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 μM of SSCrFCES inhibits the LPS-induced secretion of hTNF-α and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B. SSCrFCES is non-cytotoxic, with a clearance rate of 4.7 ml / minute. The LD90 of SSCrFCES for LPS lethality in mice is achieved at 2 μM. These results demonstrate the endotoxin-neutralizing capability of SSCrFCES in vitro and in vivo, as well as its potential for use in the treatment of endotoxin-induced septic shock. Also embodied in this application is the use of the sushi peptides and their mutant derivatives as potent antimicrobials.

The invention relates to a novel cyclic lipopeptide antibiotic (cyclic nonapeptide avermectin) and preparation and application thereof, belonging to the technical field of biomedicine. The fermentation medium is inoculated with paenibacillus, the paenibacillus is cultured at 28-35 DEG C for 24-96 hours, the fermentation broth is centrifuged to take the supernatant, the supernatant is adsorbed by a macroporous adsorption resin, and separation and purification are performed further to obtain the cyclic lipopeptide antibiotic which can be used for preparing the bacterial-infection resisting medicament. The invention provides the cyclic nonapeptide avermectin with higher toxicity than polymyxin B and higher medical application value and the preparation and application of the cyclic nonapeptide avermectin. The experiments in vitro prove that the compound can inhibit all the tested Gram-positive and negative pathogens including the multiple and super medicament resisting bacteria significantly, and the in-vivo experiments prove that the compound can prevent and treat the mouse septicemia caused by theextended-spectrum medicament resisting pseudomonas aeruginosa significantly.

An endotoxin adsorbent used for blood perfusion is prepared from agat through adding the aqueous solution to the liquid mixture of toluene and CCl4 to obtain spherical agar, activating by epoxy chloropropane under alkaline condition, reacting on diamine and then on glutaraldehyde to obtain high-strength agar beads used as the carrier of adsorbent, reacting on the amino contained ligand (polymyxin B), and reducing by NaBH4. Its advantages are high compatibility to blood and high effect on absorbing endotoxin from blood.